Recombinant Protein Tra (tra)

What are the major expression systems for recombinant proteins?

Recombinant proteins can be expressed in various host systems, each with distinct advantages. Escherichia coli remains the most widely used bacterial host due to its rapid growth, well-characterized genetics, and high protein yields. The pET vector system with T7 RNA polymerase is extremely popular and can represent up to 50% of total cell protein in successful cases . For proteins requiring post-translational modifications (PTMs), mammalian expression systems are preferred, with Chinese hamster ovary (CHO) cells being the predominant choice for biopharmaceutical production. CHO cells have become the main host cells for producing recombinant therapeutic proteins because of their ability to perform PTMs such as correct folding and glycosylation . This expression system has been used to produce 84% of the antibodies approved during 2015–2018 .

How do induction systems work in E. coli recombinant protein expression?

Induction systems in E. coli provide temporal control over recombinant protein expression. The most common system utilizes the T7 promoter technology in conjunction with IPTG (isopropyl β-D-1-thiogalactopyranoside) induction. In this system, the gene of interest is cloned behind a promoter recognized by the phage T7 RNA polymerase (T7 RNAP). The T7 RNAP gene is typically placed in the bacterial genome under the transcriptional control of a lacUV5 promoter, making it inducible by lactose or IPTG .

Alternative induction methods include:

• L-rhamnose inducible systems, which offer more tunable expression levels. At higher concentrations of L-rhamnose, more T7 lysozyme is produced, less active T7 RNAP is present, and less recombinant protein is expressed .

• Temperature-sensitive systems like the pL promoter with the mutant λcI repressor, which responds to physical signals rather than chemical cues .

What are the common challenges in recombinant protein expression?

Researchers often encounter several challenges when expressing recombinant proteins:

• Protein solubility issues and inclusion body formation

• Low expression levels due to codon bias

• Protein misfolding and degradation

• Toxicity of the expressed protein to the host cell

• Insufficient post-translational modifications

For bacterial expression systems, codon bias is a significant concern. When the cell produces massive amounts of proteins, charged tRNA availability for rare codons becomes a major determinant of expression levels . Low-abundance tRNA depletion causes ribosome stalling, leading to translation termination and failure to generate full-length products .

In mammalian expression systems like CHO cells, challenges include growth restriction, expression instability, low resistance to culture-related stresses, and high production costs. These issues can be attributed to factors affecting intracellular protein processing such as cellular secretory capacity, protein aggregation or degradation, and protein folding difficulties .

How can codon optimization enhance recombinant protein expression?

Codon optimization represents a sophisticated strategy for improving recombinant protein expression by addressing the codon bias of the expression system. The technique involves modifying the nucleotide sequence without changing the amino acid sequence to better match the tRNA pool of the host organism.

In recombinant protein production, expression rate, yield, and final product quality are all affected by the codon bias of the relevant gene and the codon bias of the expression system . Although all codons affect the translation rate, some codons are rapidly decoded while others cause ribosome pausing due to the relative cognate tRNA concentration .

Methodological approach to codon optimization:

• Analyze the codon usage bias of the target gene and host organism

• Replace rare codons with synonymous codons that are more abundant in the host

• Consider GC content at the third position of each codon

• Avoid repetitive sequences and RNA secondary structures

• Eliminate potential cryptic splice sites or internal promoters

Evidence of effectiveness: Heterologous expression of recombinant human interferon beta (rhIFN-β) gene in suspension-adapted Chinese hamster ovary (CHO-s) cells with optimized codons to increase the GC content at the third position of each codon increased the expression level by 2.8-fold .

What strategies can mitigate protein folding and secretion limitations?

Protein folding and secretion represent key bottlenecks in recombinant protein expression, particularly for complex proteins with multiple domains or disulfide bonds. When unfolded or misfolded proteins accumulate in the endoplasmic reticulum (ER) beyond its handling capacity, ER stress and unfolded protein response (UPR) are triggered, potentially leading to apoptosis and reduced yields .

Advanced strategies to address these limitations include:

• Chaperone co-expression: Co-expressing molecular chaperones (such as DnaK, DnaJ, GrpE, GroEL, and GroES in E. coli) to assist proper protein folding.

• Transcription factor engineering: Overexpression of transcription factors such as ZFP-TF, ATF4, or GADD34 has significantly increased the yield of various cellular recombinant proteins compared with parental cells, up to 10-fold .

• mTOR pathway modulation: Enhancing the ectopic expression of mammalian target of rapamycin (mTOR) gene can significantly improve cell growth, proliferation, viability, and specific productivity of secreted human glycoproteins in CHO cells. Studies have shown that an mTOR transgenic CHO-derived cell line for immunoglobulin secretion achieved a fourfold increase in antibody production (50 pg/cell/day) compared to the parental production cell line .

• 5' UTR engineering: Insertion of regulatory elements (RGEs) into the 5' untranslated region (5' UTR) RNA hairpin structure can improve expression efficiency .

How do specialized E. coli strains overcome limitations in recombinant protein expression?

Specialized E. coli strains have been engineered to address specific limitations in recombinant protein expression. Understanding their unique properties allows researchers to select the optimal strain for their target protein.

The BL21(DE3) strain and its derivatives are by far the most used strains for protein expression . Key specialized strains include:

• BL21(DE3)pLysS/pLysE: Contains the pLys plasmid expressing T7 lysozyme, which binds to T7 RNAP and inhibits transcription initiation from the T7 promoter, effectively controlling basal expression. After induction, the amount of T7 RNAP produced surpasses the level that T7 lysozyme can inhibit, enabling transcription of the recombinant gene .

• AD494 and Origami™: These K-12 derivative strains are trxB (thioredoxin reductase) mutants, enhancing disulfide bond formation in the cytoplasm. The Origami strain additionally lacks the glutathione reductase gene, further promoting disulfide bond formation .

• HMS174: A recA mutant from the K-12 lineage that exhibits improved plasmid stability. The recA mutation prevents plasmid multimer formation, an important cause of instability that relies on the recombination system of E. coli .

• BL21(DE3)CodonPlus and Rosetta(DE3): These strains contain additional tRNA genes for rare codons. BL21(DE3)CodonPlus carries the pRIL plasmid providing extra tRNAs for AGG/AGA (Arg), AUA (Ile), and CUA (Leu). The Rosetta(DE3) strain contains the pRARE plasmid, supplying tRNAs for all the above-mentioned codons plus GGA (Gly) .

A methodological consideration: While these specialized strains often improve protein production levels, they may sometimes decrease protein solubility. Research has shown that proteins with higher than 5% content of RIL codons (AGG/AGA, AUA, and CUA) are less soluble when expressed in the CodonPlus strain because the translational pauses introduced by these codons are overridden, increasing translation speed and consequently, protein aggregation .

What role does mRNA stability play in recombinant protein yields?

The stability of mRNA molecules represents a critical yet often overlooked factor affecting recombinant protein expression levels. mRNA produced during transcription is prone to degradation, and its degradation rate directly influences protein expression .

Key factors affecting mRNA stability and processing in recombinant expression systems:

• Codon selection and ribosome elongation: Studies have found that codon selection affects the rate of ribosome elongation, which in turn influences mRNA degradation rates .

• Post-transcriptional processing: Mature mRNAs undergo capping, splicing, and polyadenylation before translation. The efficiency of these processes affects mRNA stability and translational efficiency .

• Translation initiation factors: The structure and composition of eukaryotic initiation factors (eIFs) and ribosomal proteins can influence translation initiation and co-translational mRNA degradation .

Importantly, researchers should note that mRNA levels and protein expression levels are not always consistent , suggesting that post-transcriptional regulation plays a significant role in determining final protein yields. This highlights the importance of considering both transcriptional and post-transcriptional processes when optimizing recombinant protein expression systems.

How can researchers detect and address post-translational modification issues?

Post-translational modifications (PTMs) are crucial for proper protein function and are typically performed through proteolytic cleavage or covalent modification of amino acids. PTMs may lead to changes in protein characteristics and function . Detecting and addressing PTM issues requires systematic analytical approaches.

Issues with PTMs can arise from:

• Improper protein design or inappropriate DNA coding sequences

• Insufficient supply of chaperones

• Difficulty in forming interchain and intra-chain disulfide bonds

• Ineffective vesicle transport

• Adverse protein-protein interactions

Analytical methods for characterizing PTMs include:

• Mass spectrometry (MS) to identify specific modifications

• Western blotting with modification-specific antibodies

• 2D gel electrophoresis to separate protein variants

• Glycan analysis for glycoproteins

• Circular dichroism to assess secondary structure changes

For recombinant therapeutic proteins produced in CHO cells, ensuring proper glycosylation patterns that mimic human glycosylation is essential for efficacy and safety. Researchers should consider that while CHO cells can perform humanized glycosylation, there are still differences from human patterns that may need to be addressed for specific applications.

What are the indicators of ribosomal stress during recombinant protein expression?

Ribosomal stress during high-level recombinant protein expression can significantly impact protein quality and yield. Recognizing the signs of ribosomal stress allows researchers to adjust expression conditions and optimize protein production.

Common indicators of ribosomal stress include:

Ribosomes traditionally considered as mere deciphers of the genetic code also shape the transcriptome by controlling mRNA stability . During recombinant protein production, the codon bias of the gene and the expression system affect expression rate, yield, and product quality . When certain codons cause ribosome pausing due to low tRNA availability, it can trigger ribosomal stress responses.

What experimental design considerations optimize induction timing and conditions?

Optimizing induction timing and conditions is critical for maximizing recombinant protein yield while maintaining protein quality and cell viability. A systematic experimental approach should consider multiple factors:

• Growth phase for induction: For E. coli expression systems, induction at mid-log phase (OD600 0.4-0.8) typically yields optimal results, balancing biomass accumulation with metabolic capacity.

• Inducer concentration optimization: For IPTG-inducible systems, testing concentrations between 0.1-1.0 mM is recommended. Note that dose-dependent expression when using IPTG is not always predictable since IPTG can enter the cell by active transport through the Lac permease or by permease-independent pathways .

• Alternative induction systems: For more predictable dose-dependent expression, consider L-rhamnose inducible systems. When using the rhaP BAD promoter, trials with L-rhamnose concentrations from 0 to 2,000 μM should be conducted to find optimal expression conditions .

• Temperature considerations: Post-induction temperature affects protein folding and solubility. Lower temperatures (15-25°C) often improve solubility by slowing expression rate, allowing more time for proper folding.

• Induction duration: Determine optimal harvest time through time-course experiments, as extended expression periods may lead to protein degradation or cell death.

How can fusion tags be leveraged to enhance recombinant protein purification?

Fusion tags represent powerful tools for improving both the expression and purification of recombinant proteins. Beyond traditional affinity tags, stimulus-responsive tags offer innovative purification approaches.

Advanced fusion tag technologies include:

• β-roll tags: These tags allow for selective precipitation of the recombinant protein in the presence of calcium. This approach yields high-purity products and the precipitation protocol takes only a few minutes .

• Elastin-like polypeptides (ELPs): Consisting of tandem repeats of the sequence VPGXG (where X is Val, Ala, or Gly in a 5:2:3 ratio), these tags undergo an inverse phase transition at a given temperature . This property enables temperature-based purification without chromatography.

• Split-intein tags: These enable seamless protein purification through protein trans-splicing, leaving no remnant of the tag in the final product.

The methodological workflow for purification using stimulus-responsive tags typically involves:

• Expression of the fusion protein

• Cell lysis and clarification

• Application of the specific stimulus (temperature change, addition of calcium, etc.)

• Collection of the precipitated protein

• Removal of the tag if necessary (through protease cleavage or intein splicing)

This approach offers advantages including reduced purification time, lower costs by eliminating chromatography steps, and potential for higher yields through more efficient recovery.

What advances in CHO cell engineering are improving difficult-to-express proteins?

Chinese Hamster Ovary (CHO) cells have become the predominant expression system for therapeutic proteins, yet some proteins remain difficult-to-express (DTE). Recent advances in CHO cell engineering are addressing these challenges through multiple approaches.

Key strategies for improving expression of DTE proteins include:

• Cell viability enhancement: Genetic modifications targeting anti-apoptotic pathways can extend culture duration and improve yields.

• Transcription factor engineering: Overexpression of transcription factors such as ZFP-TF, ATF4, or GADD34 has been shown to increase recombinant protein yields up to 10-fold compared to parental cells .

• mTOR pathway modulation: The mammalian target of rapamycin (mTOR) plays a crucial role in protein biosynthesis. Enhanced expression of the mTOR gene significantly improves cell growth (increased cell size and protein content), proliferation (increased cell cycle progression), viability (decreased apoptosis), and robustness (decreased sensitivity to suboptimal growth factors and oxygen supply) .

• Sequence optimization beyond codons: Beyond codon optimization, researchers now consider:

  • GC content adjustment

  • Elimination of repetitive sequences

  • Removal of restriction enzyme recognition sites

  • Avoidance of RNA motifs that interfere with mRNA processing

  • Optimization of 5' untranslated regions (5' UTRs)

• Protein sequence engineering: For monoclonal antibodies, modifying sequence motifs such as complementarity determining region three can influence the rate of light chain-heavy chain dimerization during antibody synthesis, resulting in product-specific yield differences .

These advanced approaches demonstrate that overcoming DTE protein challenges requires comprehensive engineering at multiple levels—from gene sequence to cellular processes and protein structure.

What emerging technologies are expanding the capabilities of recombinant protein expression?

Recombinant protein expression technology continues to evolve rapidly, with several emerging approaches poised to overcome current limitations and expand research capabilities.

Promising emerging technologies include:

• Cell-free protein synthesis: These systems bypass cellular constraints by using purified components of the transcription/translation machinery, enabling expression of toxic proteins and rapid protein production.

• Non-canonical amino acid incorporation: Expansion of the genetic code to incorporate non-standard amino acids creates proteins with novel properties for research and therapeutic applications.

• Glycoengineering: Precise control of glycosylation patterns through cell line engineering and process optimization improves therapeutic protein efficacy and consistency.

• Machine learning approaches: Computational predictions of optimal expression conditions, codon usage, and sequence modifications are accelerating optimization processes.

• Continuous processing: Moving from batch to continuous bioprocessing improves efficiency and consistency in large-scale protein production.

Looking ahead, the integration of these technologies with advances in synthetic biology and computational design promises to further transform recombinant protein research, enabling expression of increasingly complex proteins with precisely controlled characteristics and functions.